Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss, Neurology, Endocrine, Diabetes |
| Therapuetic Areas: | Endocrinology, Neurology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 7/14/2018 |
| Start Date: | February 2015 |
| End Date: | December 30, 2018 |
| Contact: | Norman K Pollock, Ph.D. |
| Email: | npollock@augusta.edu |
| Phone: | 706-721-5424 |
Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes
Given that glutamate carboxylation or decarboxylation is key to the metabolic role of
osteocalcin (at least in mouse models) and that carboxylation is vitamin K dependent, it is
critical to isolate the effect of vitamin K manipulation on carboxylation of osteocalcin and
its subsequent effect on glucose metabolism in clinical trials. The purpose of this
randomized, double-blind, placebo-controlled clinical trial in adults is to determine whether
eight weeks of daily supplementation with vitamin K2 (menaquinone-7) can improve markers in
blood associated with diabetes risk.
osteocalcin (at least in mouse models) and that carboxylation is vitamin K dependent, it is
critical to isolate the effect of vitamin K manipulation on carboxylation of osteocalcin and
its subsequent effect on glucose metabolism in clinical trials. The purpose of this
randomized, double-blind, placebo-controlled clinical trial in adults is to determine whether
eight weeks of daily supplementation with vitamin K2 (menaquinone-7) can improve markers in
blood associated with diabetes risk.
Inclusion Criteria:
1. Healthy adults between 18 and 65 years old
2. Subject understands the study protocol and agrees to comply with it
3. Informed Consent Form signed by the subject
Exclusion Criteria:
1. Subjects using vitamin supplements containing vitamin k
2. Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic
disorders
3. Subjects presenting chronic degenerative and/or inflammatory diseases
4. Subjects receiving systemic treatment or topical treatment likely to interfere with
evaluation of the study parameters (salicylates, antibiotics)
5. Subjects receiving corticosteroid treatment
6. Subjects using oral anticoagulants
7. Subjects with a history of soy allergy
8. Subjects who have participated in a clinical study more recently than one month before
the current study
We found this trial at
1
site
1120 15th Street
Augusta, Georgia 30909
Augusta, Georgia 30909
Phone: 706-721-5424
Click here to add this to my saved trials
